Ba/F3 cell lines were used, and they either expressed wild type EML4-ALK as a model of ALK-TKI-naïve cancer, or else mutant EML4-ALK with one ALK resistance mutation, mimicking resistance following first- or second-generation ALK inhibitor treatment [74]. This evidence concerns the gene ALK and cancer.